Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
Preliminary animal studies by ourselves and others suggest that the dietary supplement,
nicotinamide riboside (NR), may improve cardiac function in heart failure (HF) by increasing
cellular levels of its metabolite, nicotinamide adenine dinucleotide (NAD+, NADH). This Study
will address a key gap in current knowledge by assessing the mechanisms through which raising
blood and myocardial NAD+ levels in humans mediates changes in mitochondrial function,
protein and epigenetic modifications, as well as inflammation. Human myocardium will be
obtained after 4-14 days of oral NR supplementation from advanced heart failure patients
undergoing elective left ventricular assist device (LVAD) implantation. Positive results
would provide evidence to proceed with further studies of NR as a mitochondria-targeted
metabolic therapy in heart failure.